Document is current
Any future updates will be listed below
-
Authors
Bergram, Martin https://orcid.org/0000-0001-8524-1900
Kechagias, Stergios
Iredahl, Fredrik
Balkhed, Wile
Holmberg, Markus
Dahlström, Nils
Lundberg, Peter
Nasr, Patrik
Ekstedt, Mattias
Rådholm, Karin
-
Funding
Funding for this research was provided by:
Linköping University
- License Information
-
More Information
Article History
Received: 18 June 2025
Accepted: 28 October 2025
First Online: 11 November 2025
Declarations
:
: The EPSOMIP study received approval from the Regional Ethical Board of Östergötland (2018/176 − 31 and 2018/494 − 32) and is registered as a clinical trial under the identifier NCT03864510 at ClinicalTrials.gov (registration date: 2019-02-12). This study was conducted in accordance with the Declaration of Helsinki. At the time of inclusion, participants received both oral and written information about the study. Those who agreed to participate provided written informed consent. Informed consent was obtained from all participants in the study.
: Not applicable.
: FI has received speaker fees and served on advisory boards for Novo Nordisk, Sanofi, and Boehringer Ingelheim. ME is the recipient of lecture fees from Novo Nordisk. PN has served on advisory boards för Boehringer Ingelheim.
